Calcium Channel Function and Blockade for Better Neurological Health

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 120

Special Issue Editors


E-Mail Website
Guest Editor
The University of Adelaide, Adelaide, Australia
Interests: dementia; cerebrovascular disease; depression; cardiovascular disease; evidence-translation

E-Mail Website
Assistant Guest Editor
Radboud University Medical Center; Donders Institute for Brain, Cognition and Behaviour; Nijmegen, The Netherlands
Interests: dementia; hypertension; blood pressure regulation; cerebral blood flow; cognition

Special Issue Information

Dear Colleagues,

Empirical work on calcium channel blockade more than 50 years ago led to landmark advances in the treatment of cardiovascular diseases. The potential for calcium channel blockade to improve neurological outcomes is only becoming realized very recently. New and emerging frontiers of research include augmentation or adjunctive use of calcium channel blockade for brain health (e.g. in bipolar depression), while genome wide association studies implicate calcium channel encoding regions in psychosis (e.g. CACNA1C). However, the mechanisms underlying calcium channels importance to neurological function are incompletely understood. The objective of this Special Issue, “Calcium Channel Function and Blockade for Better Neurological Health”, is to streamline this field of research and inform novel lines of investigation on the full spectrum of calcium channels (e.g. voltage-gated, ligand-gated) and their subunits, interactions with neurotransmitters, or pharmacological approaches to calcium channel blockade. The special issue will encompass the full scope of research and experimental designs from basic science, genetics, clinical trials, original research, and review papers.

The special issue intends to bring together research with broad application to brain health, including but not limited to stroke, cerebral vasculature, dementia, cognitive function, psychosis, bipolar disorder, depression and anxiety disorders, epilepsy, pain, neuropathy, fibromyalgia, restless legs, and alcohol withdrawal.

Dr. Phillip J. Tully
Ms. Rianne de Heus
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • calcium channels
  • calcium channel agonists
  • neurological disorders
  • neurology
  • brain health

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop